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Aims Aldosterone plays a crucial role in cardiovascular disease. ‘Systemic’ inhibition of its mineralocorticoid receptor (MR)
decreases atherosclerosis by reducing inflammation and oxidative stress. Obesity, an important cardiovascular risk
factor, is an inflammatory disease associated with increased plasma aldosterone levels. We have investigated the
role of the ‘endothelial’ MR in obesity-induced endothelial dysfunction, the earliest stage in atherogenesis.
Methods
and results
C57BL/6 mice were exposed to a normal chow diet (ND) or a high-fat diet (HFD) alone or in combination with the
MR antagonist eplerenone (200 mg/kg/day) for 14 weeks. Diet-induced obesity impaired endothelium-dependent
relaxation in response to acetylcholine, whereas eplerenone treatment of obese mice prevented this. Expression ana-
lyses in aortic endothelial cells isolated from these mice revealed that eplerenone attenuated expression of
pro-oxidative NADPH oxidase (subunits p22phox, p40phox) and increased expression of antioxidative genes
(glutathione peroxidase-1, superoxide dismutase-1 and -3) in obesity. Eplerenone did not affect obesity-induced
upregulation of cyclooxygenase (COX)-1 or prostacyclin synthase. Endothelial-specific MR deletion prevented endo-
thelial dysfunction in obese (exhibiting high ‘endogenous’ aldosterone) and in ‘exogenous’ aldosterone-infused lean
mice. Pre-incubation of aortic rings from aldosterone-treated animals with the COX-inhibitor indomethacin restored
endothelial function. Exogenous aldosterone administration induced endothelial expression of p22phox in the pres-
ence, but not in the absence of the endothelial MR.
Conclusion Obesity-induced endothelial dysfunction depends on the ‘endothelial’ MR and is mediated by an imbalance of oxida-
tive stress-modulating mechanisms. Therefore, MR antagonists may represent an attractive therapeutic strategy in the
increasing population of obese patients to decrease vascular dysfunction and subsequent atherosclerotic
complications.
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Introduction
Obesity has reached pandemic dimensions.1 In association with
insulin resistance, hypertension, and dyslipidaemia, obesity forms
the ‘metabolic syndrome’, a hallmark of cardiovascular risk.2 The
‘white’ adipose tissue (WAT) is increased in both obese mice
and humans3 and is characterized by an increase in the inflamma-
tory cytokines and oxidative stress.4 Furthermore, adipocytes can
induce aldosterone synthesis in the adrenocortical gland in an
endocrine fashion.5 As a result, visceral obesity is associated with
increased plasma aldosterone levels.6 Many of its effects are
mediated by activation of its nuclear receptor, the mineralocortic-
oid receptor (MR).
Aldosterone itself plays a crucial role in cardiovascular dis-
eases. Mineralocorticoid receptor antagonists reduce morbidity
and mortality in patients with congestive heart failure.7,8 In corre-
sponding mouse models, the beneficial effects of MR antagonism
were associated with decreased expression of inflammatory
mediators.9 Atherosclerosis is initiated at sites of endothelial
dysfunction which may be caused by enhanced generation of
COX-derived vasoconstricting prostanoids or reactive oxygen
species (ROS).10,11 The increased oxidative stress is mainly due
to a disturbed expression of ROS-producing enzymes such as
NADPH oxidase and enzymes involved in antioxidant defense
such as glucose-6-phosphate dehydrogenase (G6PDH) and gluta-
thione peroxidase (GPx).12 – 14
Pharmacological MR antagonism decreases atherosclerosis in
mice by diminishing oxidative stress and inflammation.15
Moreover, MR blockade attenuates endothelial dysfunction in
animal models of heart failure.16 MR activation induces
expression of NADPH oxidase subunits, thereby contributing
to generation of oxidative stress.17 Furthermore, aldosterone
alters expression of prostanoid-producing enzymes (enhanced)
and G6PDH (reduced) that are associated with endothelial
dysfunction.18,19
Mineralocorticoid receptor is expressed in both endothelial cells
and adipocytes. While it may induce an array of mediators involved
in endothelial dysfunction20 in the former, it acts in adipocytes as a
pro-adipogenic transcription factor.21 Pharmacological MR block-
ade using eplerenone reduces insulin resistance, macrophage infil-
tration, expression of pro-inflammatory factors, and ROS release
in WAT.22,23 Of note, the effects of MR blockade on obesity-
induced endothelial dysfunction, the role of the endothelial MR
in this context, and the corresponding molecular mediators
remain unknown.
Thus, we assessed endothelial function of lean and diet-induced
obese mice, differing in endogenous aldosterone levels, and of lean
mice with and without exogenous aldosterone infusion. Mineralo-
corticoid receptor activity was modulated by a pharmacological
and a genetic approach. As non-selective receptor binding proper-
ties of spironolactone may result in an increase in plasma cortisol24
and also thereby potentially influence endothelial function, we
used in this study, the more selective MR-antagonist eplerenone.
To address the role of the endothelial MR, we used a genetic
loss-of-function approach targeted to endothelial cells (Tie2-driven
endothelial MR deletion).
Methods
Online data supplements are available for (i) Animals, (ii) Signal trans-
duction and inflammation, (iii) Blood glucose and components of the
renin-angiotensin-aldosterone system, (iv) Analysis of vascular func-
tion, (v) Isolation of fresh aortic endothelial cells and RNA expression
analyses, and (vi) Statistical analyses.
Results
Pro-inflammatory changes in obese mice
are attenuated by eplerenone
To address the contribution of endogenous aldosterone in the de-
velopment of obesity-induced endothelial dysfunction, we exposed
6-week-old male C57BL/6 mice to a high-fat diet without (HFD) or
with eplerenone (HFD EPL). Control mice were fed a normal diet
(ND) and were considered as lean mice for the purpose of these
experiments.
To assess a putative activation of the renin–angiotensin–aldos-
terone system, aldosterone and renin plasma concentration were
measured. Aldosterone levels were significantly higher, whereas
renin concentration remained unaltered in mice fed an HFD com-
pared with lean mice (Figure 1A and B). Compared with HFD-fed
obese mice, EPL treatment of obese mice did not change plasma
renin, whereas it increased plasma aldosterone levels (Figure 1A
and B). Feeding an HFD for 14 weeks resulted in a significant in-
crease in body weight and epididymal WAT, it increased fasting
plasma glucose, and reduced glucose tolerance compared with
mice fed an ND. Treatment with EPL administered with the
HFD did not interfere with epididymal WAT and total body
weight gain. However, EPL treatment did prevent worsening of
glucose metabolism in these mice (Supplementary material
online, Table S2).
mRNA levels of pro-inflammatory cytokines such as tumour ne-
crosis factor-a (TNF-a) and monocyte chemoattractant protein-1
(MCP-1) tended to be increased (TNF-a) or were increased
(MCP-1) in the epididymal WAT of obese mice compared with
lean control mice (Figure 1C). Chronic administration of eplere-
none prevented an increase in mRNA expression levels of these
cytokines as well as macrophage-specific glycoprotein CD68 in
the epididymal WAT. These data suggest that MR antagonism
diminished the obesity-induced pro-inflammatory changes in the
epididymal WAT.
Pharmacological mineralocorticoid
receptor antagonism prevents
obesity-induced endothelial dysfunction
To determine the effects of increased endogenous aldosterone
levels in obesity on endothelial function, we performed ex vivo
aortic ring contraction/relaxation experiments with aortae from
C57BL/6 mice kept on ND, HFD, or HFD EPL, respectively
(Figure 2). Endothelium-dependent relaxation to acetylcholine
was blunted in aortae of obese mice starting at a concentration
of 3 × 1028 M of acetylcholine and reached a maximal relaxation
at 1025 M of acetylcholine. Chronic eplerenone treatment in
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obese mice prevented endothelial dysfunction (Figure 2A).
Endothelium-independent relaxation to sodium nitroprusside
(SNP) was similar in all groups (Figure 2B). Contractions to KCl
and norepinephrine (NE) were unaffected in mice fed HFD or
HFD EPL, respectively (data not shown). These findings show
that pharmacological MR antagonism prevents obesity-induced
endothelial dysfunction.
Mineralocorticoid receptor antagonism
attenuates pro-inflammatory and
pro-oxidative changes in aortic
endothelial cells of obese mice
Obesity is known to promote a pro-inflammatory, pro-oxidative,
and vasoconstricting state in the vascular endothelium, thereby
Figure 1 Plasma aldosterone is increased in obesity and further elevated by mineralocorticoid receptor antagonism; obesity-induced expres-
sion of pro-inflammatory cytokines in white adipose tissue is attenuated by mineralocorticoid receptor antagonism. C57BL/6 mice on ND, HFD,
and HFD EPL were analysed concerning (A) plasma-renin and (B) plasma-aldosterone levels; n ¼ 8–10; *P, 0.05. (C) mRNA levels of epididy-
mal fat pad in C57BL/6 mice on ND, HFD, and HFD EPL, normalized to ND levels; n ¼ 6–8; *P, 0.05 compared with ND levels, #P, 0.05
compared with HFD EPL. ND, normal chow diet; HFD, high-fat diet; HFD EPL, high-fat diet with eplerenone.
Figure 2 Mineralocorticoid receptor antagonism prevents obesity-induced worsening of endothelial function. Endothelial function studies in
C57BL/6 mice on ND, HFD, and HFD EPL. Responses of aortic rings to increasing doses of (A) acetylcholine (Ach), mediating endothelial release
of endogenous nitric oxide, and (B) sodium nitroprusside (SNP), a nitric oxide donor. See Supplementary material online, Table S4 for EC50 and
Emax values; n ¼ 8–10; *P, 0.05 for ND vs. HFD; #P, 0.05 for HFD vs. HFD EPL. ND, normal chow diet; HFD, high-fat diet; HFD EPL,
high-fat diet with eplerenone.
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inducing endothelial dysfunction. To investigate the direct effects of
obesity and eplerenone treatment on the genes expressed in aortic
endothelial cells, we developed a method to isolate fresh endothe-
lial cells from C57BL/6 mice exposed to ND, HFD, or HFD EPL
(Supplementary material online, Figure S2A and B). We observed
a slight increase in the MR mRNA expression under HFD and an
even higher increase upon additional chronic eplerenone treat-
ment (Supplementary material online, Figure S3A). Mineralocortic-
oid receptor mRNA was reduced in endothelial cells of mice in
which MR was deleted (EC MR2/2), indicating successful ablation
of endothelial MR (Supplementary material online, Figure S3B).
Analyses of mediators involved in endothelial dysfunction revealed
that prostacyclin synthase and COX-1 expression were upregu-
lated in obesity, whereas COX-2 remained unaltered (Figure 3A).
Eplerenone treatment did neither prevent HFD-induced upregula-
tion of prostacyclin synthase nor COX-1 expression. Furthermore,
endothelial nitric oxide synthase (eNOS) expression increased in
HFD EPL compared with ND mice (Figure 3A).
Figure 3 Obesity-induced pro-inflammatory and pro-oxidative changes are modulated by mineralocorticoid receptor antagonism in aortic
endothelial cells. Aortic endothelial cell mRNA levels in C57BL/6 mice on ND, HFD, HFD EPL after 14 weeks (A) prostacyclin synthase,
COX-1, COX-2, eNOS, (B) p22phox, 47phox, gp91phox, p40phox, Rac-1, (C) SOD-1, SOD-3, catalase, (D) G6PDH, GPx-1, GPx-4, normal-
ized to ND levels, n ¼ 10, *P, 0.05, #P, 0.01. ND, normal chow diet; HFD, high-fat diet; HFD EPL, high-fat diet with eplerenone.
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Given the association of aldosterone with oxidative stress, we
tested mRNA expression of NADPH oxidase subunits in isolated
aortic endothelial cells. mRNA levels of the p22phox, p47phox,
and gp91phox were not affected by diet-induced obesity.
However, additional eplerenone treatment decreased the expres-
sion of p22phox and p47phox (Figure 3B). On the other hand,
obesity increased the expression levels of p40phox and Rac-1;
the increase in p40phox was attenuated by eplerenone (Figure 3B).
mRNA expression levels of the antioxidant enzymes SOD-1 and
SOD-3 were lower under HFD compared with ND (trend for
SOD-1) and HFD EPL conditions; catalase expression remained un-
altered (Figure 3C). The mRNA expression of the ROS-scavenging
enzyme GPx-1 was enhanced by eplerenone in obesity, whereas
GPx-4 and G6PDH remained unchanged (Figure 3D).
Taken together, we observed the generation of an obesity-
induced vasoconstrictive and pro-oxidative mRNA expression
profile in aortic endothelial cells that was partially prevented by
pharmacological MR antagonism.
Endothelium-specific mineralocorticoid
receptor ablation neither affects
hyperglycaemia nor inflammation in
white adipose tissue of obese or
aldosterone-infused lean mice
To investigate theroleof theendothelialMRonobesity-induced meta-
bolic changes, we exposed EC MR2/2 mice and their corresponding
MR+/+ littermates to an ND or HFD for 14 weeks. After 14 weeks
on a HFD, both obese MR+/+ mice and EC MR2/2 showed a similar
increase in plasma aldosterone levels (Supplementary material
online, Figure S4A), weight gain, glucose intolerance (Supplementary
material online, Table S3), as well as expression of pro-inflammatory
markers MCP-1, and CD68; TNF-a was upregulated only in EC
MR2/2 mice (Figure 4A).
To test the effects of exogenous aldosterone on the endothelial
MR, we implanted osmotic minipumps containing aldosterone or
vehicle in lean MR+/+ and EC MR2/2 mice. Aldosterone infusion
for 2 weeks increased plasma aldosterone to the same extent in
both EC MR2/2 and MR+/+ mice kept on ND (Supplementary ma-
terial online, Figure S4B) and did not induce the expression of
TNF-a, MCP-1, or CD68 in the epididymal WAT (Figure 4B).
These data indicate that endothelial MR deletion neither affects
glucose tolerance nor the pro-inflammatory state of the WAT of
obese or aldosterone-infused lean mice.
Deletion of the endothelial
mineralocorticoid receptor prevents
obesity- or exogenous aldosterone-induced
endothelial dysfunction to a similar extent
as does COX inhibition
To determine whether obesity-induced endothelial dysfunction
was mediated by the endothelial MR, we exposed EC MR2/2
and MR+/+ mice to ND or HFD for 14 weeks. Compared with
lean controls, obese MR+/+ mice demonstrated a significant im-
pairment of endothelium-dependent vasodilation, whereas MR de-
letion in endothelial cells prevented endothelial dysfunction
(Figure 5A). Of note, aortic walls of obese MR+/+ mice contained
no macrophages (Supplementary material online, Figure S5). Infu-
sion of aldosterone for 2 weeks using minipumps blunted endothe-
lial function in lean mice. Genetic deletion of the endothelial MR
prevented endothelial dysfunction (Figure 5B). Thus, the endothe-
lial MR mediates both obesity-induced endogenous as well as ex-
ogenous aldosterone-induced endothelial dysfunction.
COX inhibition using indomethacin normalized endothelial func-
tion in aldosterone-infused lean mice to the same extent as endo-
thelial MR deletion (Figure 5C). Therefore, aldosterone induces
endothelial dysfunction by activating COX-dependent pathways.
Aldosterone-infused endothelium-specific
MR2/2 lean mice exhibit pro-inflammatory
changes in aortic endothelial cells
Next we evaluated the effects of aldosterone infusion or MR abla-
tion on mediators of inflammation, vasoconstriction, and oxidative
Figure 4 The obesity-induced increase in the expression of
pro-inflammatory cytokines in white adipose tissue is independ-
ent of endothelial mineralocorticoid receptor; aldosterone infu-
sion in lean animals does not induce inflammation. mRNA
levels of the epididymal fat pad in wild-type (MR+/+) and
endothelial-specific MR knockout (EC MR2/2) mice (A) on ND
or HFD and (B) vehicle- or aldosterone-infused, standardized
to S12 and normalized to ND levels; n ¼ 6–8; *P, 0.05 for
MR+/+ ND vs. MR+/+ HFD; #P, 0.05 for EC MR2/2 ND vs.
EC MR2/2 HFD. ND, normal chow diet; HFD, high-fat diet.
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stress in aortic endothelial cells. For this purpose, we isolated fresh
aortic endothelial cells from lean MR+/+ and EC MR2/2 mice
infused with aldosterone for 2 weeks and determined mRNA ex-
pression by qPCR. Our analyses showed that prostacyclin synthase
expression was enhanced by exogenous aldosterone, independent
of the presence of endothelial MR (Figure 6A); in contrast,
aldosterone-induced COX-1 expression was decreased in EC
MR2/2 mice, whereas COX-2 and eNOS expression remained
unchanged.
Analyses of enzymes enhancing oxidative stress revealed that
mRNA expression of the NADPH oxidase subunit p22phox was
upregulated by aldosterone, whereas this effect was abolished in
EC MR2/2 mice; gp91phox remained unaltered in all conditions
(Figure 6B). Expression levels of the NADPH oxidase subunits
p47phox, p40phox, and Rac-1 were below the detection limit
(data not shown). Regarding antioxidant enzymes, expression of
SOD-1 mRNA was decreased by aldosterone, but did not reach
statistical significance (P ¼ 0.077). SOD-3 mRNA was decreased
upon aldosterone infusion and remained low in EC MR2/2 mice,
both in the presence or absence of aldosterone (Figure 6C).
Catalase could not be detected (data not shown). ROS-scavenging
enzymes GPx-1, GPx-4, and G6PDH remained unaltered in all
conditions (Figure 6D). Thus, aldosterone enhances the expression
of mediators involved in the generation of ROS and prostanoids in
an endothelial MR-dependent manner.
Discussion
Principle findings
This experimental study provides three main novel findings
(Figure 7): (i) diet-induced obesity generates endothelial dysfunc-
tion by enhancing expression of NADPH oxidase and through ac-
tivation of COX-1-dependent pathways in freshly isolated aortic
endothelial cells; (ii) genetic deletion of the endothelial MR pre-
vents obesity- as well as aldosterone-induced endothelial dysfunc-
tion without affecting glucose tolerance or pro-inflammatory
pathways in the WAT; (iii) activation of the endothelial MR is suf-
ficient to induce endothelial dysfunction, in part via increased
endothelial p22phox expression.
Figure 5 Loss of endothelial MR prevents obesity-induced endothelial dysfunction and COX inhibition restores aldosterone-induced endo-
thelial dysfunction. The vascular response of aortic rings pre-constricted with norepinephrine to increasing doses of the endothelium-
dependent vasodilator acetylcholine (Ach) was measured in wild-type (MR+/+) and endothelial-specific MR knockout (EC MR2/2) mice;
n ¼ 6–8. (A) MR+/+ and EC MR2/2 mice on ND and HFD; *P, 0.05 for MR+/+ ND vs. MR+/+ HFD; #P, 0.05 for MR+/+ HFD vs. EC
MR2/2 HFD; $P, 0.05 for MR+/+ HFD vs. EC MR2/2 ND. (B) MR+/+ and EC MR2/2 mice after aldosterone or vehicle infusion;
*P, 0.05 for MR+/+ vehicle vs. MR+/+ aldo; #P, 0.05 for MR+/+ aldo vs. EC MR2/2 aldo; $P, 0.05 for MR+/+ aldo vs. EC MR2/2
vehicle. (C) MR+/+ on ND and HFD or after aldosterone or vehicle infusion; rings were pre-treated for 30 min with indomethacin. See Sup-
plementary material online, Table S4 for EC50 and Emax values. *P, 0.05 for MR+/+ aldo vs. MR+/+ aldo (indomethacin-treated); #P, 0.05 for
MR+/+ aldo vs. EC MR2/2 aldo; $P, 0.05 for MR+/+ aldo vs. EC MR2/2 aldo (indomethacin-treated). ND, normal chow diet; HFD, high-fat diet.
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Added value of this study
Our study provides added value in the following contexts:
In mice fed an HFD, we observed an increase in plasma aldoster-
one. This effect was more pronounced if mice were pre-treated
with eplerenone; renin levels remained unaltered. This is in line
with publications showing a positive correlation between obesity
and plasma aldosterone levels independent of plasma renin activ-
ity.25,26 Since adipocytes induce the release of aldosterone by adre-
nocortical cells,27 we propose a renin-independent mechanism in
obesity that stimulates aldosterone secretion. We observed a
further increase in plasma aldosterone levels upon eplerenone
therapy corroborating previous findings.28,29 This phenomenon is
likely related to a displacement of the mineralocorticoid from its
receptor and/or its enhanced production during MR blockade
due to a positive physiological feedback loop. We show for the
first time that deletion of endothelial MR does not increase
plasma aldosterone levels. Thus, we propose that the endothelial
MR is not involved in the regulatory feedback loop that induces
eplerenone-induced aldosterone production.
Our data reveal that pharmacological MR blockade in
diet-induced obesity improved glucose tolerance. In line with our
observation, MR antagonism has been reported to reduce insulin
resistance in genetically obese mice.23 Obesity-associated
pro-inflammatory changes in WAT can contribute to the
Figure 6 Aldosterone-induced expression of COX-1 and reactive oxygen species-generating enzymes in endothelial aortic cells depend on
endothelial mineralocorticoid receptor. Aortic endothelial cell mRNA levels in wild-type (MR+/+) and endothelial-specific MR knockout
(EC MR2/2) mice after aldosterone or vehicle infusion (A) prostacyclin synthase, COX-1, COX-2, eNOS, (B) p22phox, gp91phox, (C)
SOD-1, SOD-3, (D) G6PDH, GPx-1, GPx-4, standardized to S12 and normalized to ND levels; n ¼ 6–8; *P, 0.05. ND, normal chow diet.
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development of insulin resistance.30 We and others22 demon-
strated that eplerenone decreases mRNA of pro-inflammatory
cytokines in WAT. Moreover, we extend these findings by
showing for the first time that endothelial MR ablation neither pre-
vents impaired glucose tolerance nor increases the expression of
pro-inflammatory mediators in the obese WAT. Thus, endothelial
MR signalling is neither involved in these obesity-induced diabetic
nor pro-inflammatory changes.
Genetically obese mice develop endothelial dysfunction.31 In the
current study, pharmacological MR antagonism prevented endo-
thelial dysfunction in diet-induced obesity, suggesting that activa-
tion of MR with a concomitant release of inflammatory
molecules impaired endothelium-dependent relaxation. Notably,
endothelium-specific MR deletion completely prevented both
diet- and aldosterone-induced endothelial dysfunction. These
novel findings demonstrate that activation of the endothelial MR
is sufficient to mediate endothelial dysfunction in diet-induced
obesity.
Aldosterone increases expression of COX-2, prostacyclin pro-
duction,32 and vascular inflammation.33 In the context of
diet-induced obesity with increased endogenous aldosterone
levels, we observed that COX-1 was upregulated in freshly isolated
aortic endothelial cells. Mineralocorticoid receptor antagonism did
not attenuate this increased COX-1 expression. Our endothelial
function studies revealed that pre-treatment of aortic rings with
the COX inhibitor indomethacin completely normalized
endothelium-dependent relaxations in response to acetylcholine
in obese mice. Similar effects were observed in spontaneously
hypertensive rats.11 Our results corroborate another study report-
ing that obesity induces endothelial dysfunction in a COX-1-
dependent manner.34 Analyses of the prostacyclin synthase
revealed that both diet-induced obesity as well as exogenous al-
dosterone administration enhanced expression of prostacyclin syn-
thase in aortic endothelial cells. In line with our observation, it has
been shown that prostacyclin increased endothelial dysfunction in
hypertensive rats.32 Furthermore, inhibition of COX that produces
prostacyclin synthase substrates, restores aldosterone-induced
endothelial dysfunction.35 Of note, neither pharmacological MR an-
tagonism in diet-induced obesity, nor genetic endothelial-specific
MR deletion during aldosterone infusion attenuated prostacyclin
synthase expression. These findings imply that increased endogen-
ous aldosterone in obesity induces vasoconstricting prostanoids in-
dependent of the endothelial MR. It is likely that aldosterone acts
in this context by non-genomic effects.36 A more detailed mechan-
istic insight would be of interest. However, we consider the corre-
sponding analyses beyond the scope of the current study.
We demonstrate that diet-induced obesity was associated with
an increased expression of the pro-oxidant NADPH subunits
(p40phox and rac-1) as well as a reduced expression of the anti-
oxidant proteins SOD-1 and -3. Thus, increased ROS production
may contribute to endothelial dysfunction. Indeed, the endothelial
MR mediates superoxide generation via Rac-1 activation.17 This is
in line with our observation that MR antagonism in obesity con-
ferred beneficial effects on the expression of the NADPH
Figure 7 Mechanisms of aldosterone-induced endothelial dysfunction in obesity. The expression of NADPH oxidase subunit p22phox can be
blocked by both eplerenone and endothelial mineralocorticoid receptor ablation. Therefore, p22phox seems to be the crucial mediator in in-
ducing aldosterone-induced endothelial dysfunction in aortic endothelial cells of obese mice through genomic (solid arrow) or non-genomic
(dashed arrow) effects.
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oxidase subunits (p22phox, p47phox, p40phox, and rac-1), anti-
oxidant enzymes SOD-1 and -3, and the ROS scavenging
enzyme GPx-1. Exogenous aldosterone administration modulated
exclusively the NADPH oxidase subunit p22phox mRNA expres-
sion in aortic endothelial cells in an MR-dependent manner. Since
endothelial MR ablation is sufficient to abolish both obesity- and
exogenous aldosterone-induced endothelial dysfunction, we pos-
tulate that the endothelial MR-mediated p22phox expression is
sufficient to increase a pro-oxidative pathway leading to endothe-
lial dysfunction.
Overexpression of endothelial MR in mice fed a normal chow
induces an enhanced vasoconstrictive response in resistance arter-
ies with a mild hypertension. However, these vessels do not
exhibit signs of endothelial dysfunction nor increased oxidative
stress.37 Differences in experimental settings (our study:
diet-induced obesity, high cholesterol diet, and constitutive EC
MR expression) are likely to account for the diverse findings.
Potential limitations
We provide evidence of increased endothelial MR expression in
obese compared with lean mice and of a lack of MR expression
in endothelial cells of EC MR2/2 mice—all at the DNA and
RNA level. Despite extensive efforts, we did not succeed in visu-
alizing MR expression at the protein level using various lots of pre-
viously described antibodies.38 Since the knockout procedure
consistently deletes the gene, we consider that our data provide
solid evidence for MR deletion in endothelial cells. As the Tie2
promotor used to drive MR deletion in endothelial cells is also
active in myeloid cells, we cannot conclude that endothelial pro-
tection seen in EC MR2/2 mice is due exclusively to endothelial
MR ablation.39 Indeed, we observed MR ablation in macrophages
of EC MR2/2 mice. Moreover, MR ablation in macrophages
reduces MR-mediated cardiac pro-inflammatory responses in a
mouse model of cardiac fibrosis.40 Since we found no macrophages
in the aortae of obese mice with intact MR and we observed
similar pro-inflammatory expression patterns in the WAT of
obese EC MR2/2 and MR+/+ mice, we propose that Tie2-driven
ablation of MR in adipose tissue macrophages is unlikely to contrib-
ute to endothelial protection in diet-induced obesity in EC MR2/2
mice.
Blood pressure in the different animal groups was not assessed,
although a minor increase in blood pressure of obese animals and a
decrease in mice lacking the endothelial MR are possible. Indeed,
increased blood pressure has been observed upon exogenous al-
dosterone administration19 and in mice with endothelium-specific
MR overexpression.37 Thus, changes in blood pressure could
have taken place and may have modified aortic endothelial gene
expression and participated in the observed alterations of endo-
thelial function.
Conclusions and possible
implications
We demonstrate that both endogenous aldosterone in obesity as
well as exogenous aldosterone cause endothelial dysfunction by
inducing expression of ROS-generating enzymes in an endothelial
MR-dependent fashion and by activating the COX-1 pathway inde-
pendent of the endothelial MR. Pharmacological MR blockade
abolishes obesity-induced glucose intolerance, adipose tissue in-
flammation, and endothelial dysfunction. Genetic ablation of the
MR in endothelial cells identifies the endothelial MR as a crucial
mediator of obesity-induced endothelial dysfunction (Figure 7). In
addition, changes in blood pressure secondary to endothelial MR
ablation and/or the deletion of the MR in macrophages may have
contributed to the observed prevention of obesity-induced
effects by Tie2-driven MR deletion.
Our experimental findings have the following potential clinical
implications: MR-antagonizing drugs appear worth testing for
endothelial function in the rapidly growing population of obese
patients that are particularly prone to atherosclerosis, hyperten-
sion, and insulin resistance.
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